Items tagged with Scientific research

Funding to discover and validate novel biomarkers, diagnostics for TB diagnosis (post)

NIAID recognizes a need for non-sputum-based tuberculosis (TB) diagnostics for use in HIV-1-infected and HIV-1-exposed uninfected children to improve and simplify rapid and decentralized diagnosis of TB disease. To support biomarker discovery and biomarker-based assay development, NIAID will fund R01 research projects through the new funding opportunity announcement (FOA) Advancing Biomarker Discovery and Novel Point-of-Care Diagnostics for Active TB Disease Detection in HIV-1 Infected and Exposed Children (R01, Clinical Trial Optional).

New tools and strategies for TB diagnosis, care, and elimination: A PLOS Medicine Special Issue (post)

New articles were included in the Special Issue, released by PLOS Medicine in the beginning of April, focusing on new approaches to fighting and ending TB, including discovery and validation of novel biomarkers and diagnostic technologies, development of new treatments, testing of vaccines, and implementation studies of new strategies for diagnosis and treatment of TB.

TB Alliance and partners form multidisciplinary center for translational TB drug research (post)

NEW YORK, NY (May 9, 2019)—The National Institute of Allergy and Infectious Diseases (NIAID) has awarded TB Alliance a Center of Excellence in Translational Research (CETR) grant (U19AI142735) for tuberculosis (TB) drug development. New translational research to develop novel anti-TB medicines is being carried out with partners at the University of Illinois at Chicago, Harvard University, Johns Hopkins University, and Research Triangle Institute.

Drug-resistant TB reversed in lab (post)

About 1.5 million people died of tuberculosis (TB) in 2017, making it the most lethal infectious disease worldwide. A growing rise in drug-resistant TB is a major obstacle to successfully treating the illness.

Researchers find genetic link to TB (post)

About one in five people are infected with Mycobacterium tuberculosis, the microbe that causes tuberculosis. Most, however, will never develop symptoms; and for decades researchers have been stumped as to why some people are more vulnerable to the bacterium than others. Now, Rockefeller scientist Jean-Laurent Casanova has identified a genetic condition that makes the immune system susceptible to mycobacterial attack.

Phage therapy treats patient with drug-resistant bacterial infection (post)

Summary

Scientists have used an experimental therapy that relies on bacteria-infecting viruses collected, in part, through HHMI’s SEA-PHAGES program to fight a Mycobacterium infection in a 15-year-old girl.

Report of the High-level consultation on accelerating the development of the M72/AS01E TB vaccine candidate (post)

The High-level consultation on accelerating the development of the M72/AS01E tuberculosis vaccine candidate was convened by the World Health Organization on 5 April 2019.

Researchers identify faster, more effective drug combination regimens to treat TB (post)

Tuberculosis is a potentially deadly though curable disease. Each year about 10 million people develop active cases, and 1.6 million people die. In addition, about 1.7 billion people around the world are infected with TB bacteria, which can lie dormant for weeks to years, then become active and cause disease in up to 10 percent of those who are infected.

New research could lead to TB drug breakthrough (post)

Researchers have made a breakthrough that could eventually lead to a more effective treatment for tuberculosis.

Researchers study resistance to ‘protect’ anti-TB drug (post)

Scientists from Stellenbosch University are trying to conserve the life-saving treatment bedaquiline, by studying how the bacterium that causes TB can develop resistance to this drug.